Researchers report progress on safer delivery after death in Capsida gene therapy brain trial
Following a patient death in a gene therapy trial targeting a brain disease, investigators say they have identified approaches to reduce the risks associated with crossing the blood–brain barrier.
STAT News reports that researchers have shared updated findings following an unexpected patient death in a gene therapy trial run by Capsida Biotherapeutics, a company focused on central nervous system gene delivery. The death occurred during a trial designed to deliver a gene therapy across the blood–brain barrier, a notoriously difficult technical challenge in neurological gene therapy.
According to the STAT News report, the incident prompted investigators to examine the mechanisms underlying the adverse event, and some researchers now believe they have identified approaches that may reduce the associated risks — though the report does not specify which disease the trial targets beyond its broad neurological context, nor does it detail the specific mitigation strategies in peer-reviewed form.
The story is relevant context for the ongoing discussion around the safety of viral vector-based gene therapy, particularly high-dose delivery to the central nervous system. It follows the broader conversation documented in earlier Genetic Current coverage around AAV-associated oncogenicity and pharmacovigilance. The underlying investigation has not yet produced published peer-reviewed safety data; this is news reporting on work in progress. Researchers, clinicians, and regulators monitoring gene therapy safety will find the development noteworthy.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-11-17STAT+: After death in gene therapy trial for a brain disease, progress is reported